Spero Therapeutics, Inc. Net Income Loss

Quick Answer

Spero Therapeutics, Inc. reported Net Income Loss of -$41.66 million for the year ending 2018.

  • Spero Therapeutics, Inc. showed a decrease of -7.5% in Net Income Loss from 2017 to 2018.
  • This data is from Spero Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 14, 2019.
  • XBRL data for this metric is available from 2015 to 2018 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2015 to 2018), Spero Therapeutics, Inc.'s Net Income Loss has declined by 310.3%.
  • Historical annual values: Fiscal year 2018: -$41.66 million | Fiscal year 2017: -$38.74 million | Fiscal year 2016: -$25.49 million | Fiscal year 2015: -$10.15 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: